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Summary
We performed genomic, epigenomic, transcriptomic and proteomic characterizations of uterine 
carcinosarcomas (UCSs). Cohort samples had extensive copy number alterations and highly 
recurrent somatic mutations. Frequent mutations were found in TP53, PTEN, PIK3CA, PPP2R1A, 
FBXW7 and KRAS, similar to endometrioid and serous uterine carcinomas. Transcriptome 
sequencing identified a strong epithelial-to-mesenchymal transition (EMT) gene signature in a 
subset of cases that was attributable to epigenetic alterations at microRNA promoters. The range 
of EMT scores in UCS was the largest amongst all tumor types studied via The Cancer Genome 
Atlas. UCSs shared proteomic features with gynecologic carcinomas and sarcomas with 
intermediate EMT features. Multiple somatic mutations and copy number alterations in genes that 
are therapeutic targets were identified.
Keywords
Uterine carcinosarcoma; endometrial cancer; the cancer genome atlas; translational science; 
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Introduction
Uterine carcinosarcomas (UCSs) are rare, aggressive, biphasic neoplasms that are defined as 
tumors consisting of high-grade malignant epithelial and mesenchymal elements (Kurman et 
al., 2014). They account for less than 5% of all uterine malignancies. The mesenchymal 
component may contain cell types native to the uterus, which are termed “homologous”, or 
extra-uterine histologic subtypes, which are termed “heterologous”. Homologous 
components usually resemble high-grade undifferentiated sarcoma or fibrosarcoma, and 
heterologous components frequently appear to be rhabdomyosarcomas or chondrosarcomas. 
At the time of diagnosis, approximately one third of patients present with disease that has 
spread beyond the uterus (Bland et al., 2009; Kurman et al., 2014). Five-year progression-
free survival for disease confined to the uterus at diagnosis is 40–75%, compared to 20–35% 
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for disease with extra-uterine extension (Ferguson et al., 2007; Yamada et al., 2000). 
Reported risk factors for developing UCS include prior pelvic radiotherapy and exposure to 
tamoxifen (Brinton et al., 2013; Pothuri et al., 2006). Heterologous differentiation is a 
prognostic feature associated with a higher risk of tumor recurrence, particularly when 
present in early-stage disease (Ferguson et al., 2007; Lopez-Garcia and Palacios, 2010).
UCSs were thought to develop either from a collision between independent, geographically 
adjacent carcinomas and sarcomas (collision theory) or as a combination of cellular masses 
that underwent early divergence from a common precursor stem cell (combination theory) 
(McCluggage, 2002). Recent evidence suggests that most tumors are monoclonal in origin, 
with late divergence and metaplasia of the carcinoma into the sarcomatous components 
(conversion theory). Both components—carcinoma and sarcoma—express many similar 
immunohistochemical markers, share common somatic mutations and often have identical 
patterns of X-chromosome inactivation (Kounelis et al., 1998; Thompson et al., 1996; Wada 
et al., 1997). Additional studies using polymorphic microsatellite markers in both 
components demonstrated strongly shared patterns of loss of heterozygosity indicative of 
late patterns of divergent evolution (Abeln et al., 1997; Fujii et al., 2000). By resolving the 
clonal origins of UCSs, we will better understand patterns of metastases and approaches to 
therapeutic targeting.
Prior work that included 13 non-hypermutated UCS tumors found a high frequency of TP53 
mutations and lower frequencies of FBXW7, PIK3CA and PPP2R1A mutations (Jones et al., 
2014). Many of the mutations in chromatin-remodeling genes were found in hypermutated 
UCS samples or in carcinosarcoma tumors of ovarian origin. A recent publication of 24 non-
hypermutated UCS tumor-normal exomes found lower frequencies of TP53 and FBXW7 
mutations (Zhao et al., 2016). The purpose of this study was to conduct a comprehensive, 
multi-platform analysis of adjudicated UCS cases to identify key molecular insights into 
tumorigenesis.
Results
Samples and clinical data
Primary tumor samples and corresponding germline DNA were collected from 57 untreated 
patients with UCS who had a mean age of 70 years. Local Institutional Review Boards 
approved all tissue acquisition. Only cases that cleared rigorous pathology review were 
included. Three expert gynecological pathologists microscopically examined virtual slides 
prepared from hematoxylin and eosin–stained glass slides to ensure that tumors met WHO 
2014 criteria and to exclude histologic mimics of UCS. Annotated morphologic data 
included carcinoma and sarcoma type, presence of heterologous differentiation and 
percentage distribution of carcinomatous and mesenchymal components. Clinical and 
pathological characteristics of the samples generally reflect a cross-section of individuals 
with UCS (Table S1). The median follow-up of the cohort was 25.7 months (range, 1–104 
months); 64% of the patients had disease recurrence, and 58% died during follow-up. 
Comprehensive molecular analyses were performed at independent centers using six 
genomic, epigenomic or proteomic platforms (Supplemental Experimental Procedures).
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Somatic alterations
Exome sequencing of all 57 UCS tumors identified 9149 somatic mutations based on 
consensus calls from four mutation-detection algorithms (Table S2). From this set of 
mutations, we selected 492 sites for independent hybrid-capture validation, representing 161 
genes from lists of significantly mutated genes in this study (below and Supplemental 
Experimental Procedures) as well as The Cancer Genome Atlas (TCGA) endometrioid 
endometrial cancer (UCEC) study. Of 417 sites with sufficient coverage to be 99% powered 
to validate mutations, 99.5% of these mutations were validated (376 of 378 single-nucleotide 
variants and all 35 indels). Similar to other gynecologic tumors, the median non-silent 
mutation density of this cohort was 1.59 mutations/Mb; however, a single tumor had an 
elevated mutation density of 120 mutations/Mb (Figures 1A and S1A), likely due to a 
mutation in the DNA polymerase gene POLE. Analysis of mutational signatures also 
identified an APOBEC signature with C>T and TC>AA/T substitutions in a single tumor 
that had elevated expression of several APOBEC3 genes (Figure S1B). Combined analysis 
using multiple versions of MutSig identified 14 significantly recurring mutations, many of 
which were also recurrent mutations in uterine endometrial cancer (Figure 1B and Table S3) 
(Cancer Genome Atlas Research et al., 2013; Lawrence et al., 2014; Lawrence et al., 2013). 
Most prominent were TP53 mutations, which were found in all but five tumors (91%). 
Approximately half of the UCS tumors had mutations in one or more of the PI3-kinase 
pathway genes—PIK3CA (35%), PTEN (19%) or PIK3R1 (11%). However, unlike previous 
studies of endometrial tumors where PTEN and TP53 mutations tended to be mutually 
exclusive and confined to one of the two common histologic subtypes (endometrioid or 
serous), eight (73%) of 11 tumors with PTEN mutations also had a TP53 mutation. Other 
significantly mutated genes shared with endometrioid or serous endometrial tumors included 
FBXW7 (28%), PPP2R1A (28%), CDH4 (18%), KRAS (12%), ARID1A (12%), 
ARHGAP35 (11%) and SPOP (7%). Genes that were significantly mutated in UCS but not 
in endometrial carcinomas include the tumor suppressor RB1 (11%) and the splicing factor 
U2AF1 (4%), which was twice mutated at a hotspot (p.S34F) also found in lung 
adenocarcinoma and acute myeloid leukemia tumors. The transcription factor ZBTB7B 
(11%) is a gene that was significantly mutated only in UCS. TP53 and KRAS hotspots are 
ubiquitous in many cancer types. The PIK3CA hotspots p.E545K and p.H1047R are the two 
most commonly reported mutated PIK3CA sites in this study and in cancer overall 
(COSMIC v78), both leading to a constitutively active enzyme. PTEN and ARHGAP35 
mutations were more common in the few tumors without identified TP53 mutations. 
Through analysis of RNA sequencing data, three samples were found to have kinase-domain 
gene fusions (NUP210-MAST1, CENPP-WNK2 and DDX6-ALK) based on the consensus 
of two fusion-detection approaches (Supplemental Experimental Procedures). No recurring 
fusions leading to an in-frame protein were detected in this cohort. One sample was 
dominated by the APOBEC mutation signatures, whereas two samples showed 
microsatellite instability, and the sample with the highest mutation rate had a mutation in 
POLE (Figure 1C).
Single nucleotide variants (SNVs) stratified by 96 tri-nucleotide base substitutions and 
indels grouped by the number of inserted or deleted bases identified four mutational 
signatures (Figure 1D). The APOBEC signature was characterized by C>T/G at TCW 
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(W=A/T), the POLE signature had a predominance of C>A at TCT and C>T at TCG, the 
microsatellite instability (MSI) signature had a significant enrichment of one-base indels, 
and the spontaneous deamination signature was dominated by C>T at CpG di-nucleotides.
Somatic copy number alterations in 56 of 57 UCSs were determined using SNP 6.0 Arrays 
(Affymetrix). Most tumors were aneuploid with frequent arm- and focal-level alterations 
(Figures 1E and S2A). Analysis of ploidy and whole-genome doubling using the 
ABSOLUTE algorithm predicted that this cohort had a median ploidy of 3.3 and that 90% of 
the tumors had undergone at least one whole-genome-doubling event (Carter et al., 2012). 
This percentage is significantly higher than in serous ovarian tumors (54%, p < 0.001 
Fisher’s exact test), the tumor type with the next highest frequency of genomic doubling in 
TCGA (Zack et al., 2013). GISTIC 2.0 analysis (Mermel et al., 2011) of significantly 
reoccurring copy number alterations identified 25 regions of focal amplifications and 37 
regions of focal deletion (Table S4). Recurring focal amplifications include those containing 
the oncogenes TERC (3q26.2), FGFR3 (4p16.3), MYC (8q24.21), KAT6A (10q22.2), 
MDM2 (12q15), ERBB2 (17q12), CCNE1 (19q12) and BCL2L1 (20q11.21) (Figures 1E 
and S2B). A 1q22 amplification containing the recently discovered oncogene RIT1 (Berger 
et al., 2014), which was focally amplified in serous endometrial tumors, was also present. 
Recurring focal deletions contained the tumor suppressors PTPRD (9q23) and RB1 
(13q12.2).
Analysis of clinically relevant somatic alterations was conducted using the PHIAL algorithm 
(Figures 2A) (Van Allen et al., 2014). Potentially actionable PI3-kinase-related alterations 
were found in 42.1% of patients. These alterations included somatic mutations in PIK3CA, 
PIK3R1 and PTEN, in addition to homozygous deletions of PTEN and NF1. Alterations 
were also identified in AKT/mTOR targets in 32% of patients, including frequent mutations 
in FBXW7, AKT2 and STK11. Together, 62% of tumors had one or more potentially 
clinically relevant alteration in the PI3K/AKT/mTOR pathway. Recurrent hotspot mutations 
were seen in PIK3CA and PPP2R1A (Figure 2B). Potentially clinically relevant alterations 
in cell cycle genes were found in 22.8% of patients, including somatic mutations in CCND1, 
CDKN2B; high-level amplification of CCNE1; and homozygous deletion of CDKN2A and 
CDKN2B. Potentially actionable alterations were also found in multiple cases for somatic 
mutations in ERBB2, ERBB3, BRCA2, and homozygous deletion of ATM. Mutations in 
chromatin remodeling genes including ARID1A and CHD4 were common and are becoming 
potentially actionable (Figure 2B). Single cases with FGFR2 and SMARCA4 mutations and 
an in-frame fusion with ALK were identified. Taken together, these data provide a rationale 
for the use of sequence-based diagnostics to direct patients with UCS to targeted therapy.
ABSOLUTE was used to predict the clonality of mutations, including an adjustment for 
cellularity (Figure 3A). Seventy-three percent of all mutations (Figure 3B) and 82% of those 
in significantly mutated genes (Figure 3C) were found to be clonal, which is similar to the 
frequencies seen in most other solid tumor types. The high clonal proportion of UCS 
mutations is consistent with mutations from bladder urothelial carcinoma, lung 
adenocarcinoma, lung squamous cell carcinoma, skin cutaneous melanoma, and stomach 
adenocarcinoma. This high degree of clonality in UCS is also consistent with the tumor 
being derived from a single cell of origin. A lower degree of clonality would be expected 
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from the merger of two histologically distinct (collision) tumors, as well as from a tumor 
that diverged early from a common precursor (combination theory), resulting in greater 
differentiation between cell populations. These findings are consistent with the conversion 
theory of UCS metaplasia from an epithelial precursor.
Based on prior work from TCGA and others (Cancer Genome Atlas Research et al., 2013; 
McConechy et al., 2012), we classified 55 of the 57 UCS samples as endometrioid-like or 
serous-like based on the presence of PTEN, ARID1A, PPP2R1A and/or TP53 somatic 
mutations (Table S3). Two samples were not classified because one was an ultramutated 
sample with a POLE mutation and one sample had no mutations in any of the classification 
genes. Of the 55 classified cases, 12 (22%) were endometrioid-like and 43 (78%) were 
serous-like. All 10 stage IV patients were classified as serous-like. Histologically, the 
endometrioid-like cases were more likely to have leiomyosarcoma components (p = 0.05) 
and the serous-like cases were more likely to have rhabdomyosarcoma components (p = 
0.04, Table S1). There were no significant differences in progression-free or overall survival 
based on histologic subtype (data not shown).
Mesenchymal features of UCS
EMT is a process in which epithelial cells undergo loss of polarity and other changes that 
enable them to develop a mesenchymal phenotype. EMT is associated with greater 
metastatic potential (Radisky, 2005). Although different tumor types exhibit varying levels 
of EMT, studies have suggested that non-gynecologic carcinosarcomas (e.g., breast) might 
be examples of complete EMT (Sarrio et al., 2008). Using array-based gene expression 
profiling, an EMT phenotype has been suggested in a subset of UCS tumors (Chiyoda et al., 
2012).
To quantify per-sample EMT levels across multiple tumor types and in our cohort, we 
calculated EMT scores based on a 76-gene signature (Byers et al., 2013). The EMT score 
provides a quantitative phenotypic measurement in which lower scores correspond to an 
epithelial phenotype and higher scores correspond to a mesenchymal phenotype. Based on 
EMT scores, high expression levels of many microRNAs (miRNAs), including all members 
of the miR-200 family, were significantly correlated with epithelial phenotype tumors 
(Figure 4). This result is noteworthy because the miR-200 family may have therapeutic 
relevance (Cortez et al., 2014). We also found a strong negative association between the 
expression of these miRNAs and their promoter methylation levels (Figure 4), which 
demonstrates epigenetic regulation of the miR-200 family and perhaps indicates a 
mechanism for the EMT in UCS. The significant association of EMT scores extends to 
expression of E-cadherin at the gene and protein levels, as well as to CDH1 regulators 
SNAI1/2 and ZEB1/2, which are direct miR-200 family targets. EMT scores were also 
higher in tumors with histologic findings that showed heterologous differentiation.
Seven miRNA clusters were identified, suggesting that our cohort was molecularly 
heterogeneous (Figure S3A). We noted that miRNA cluster 1 had relatively high EMT 
scores and low miR-200b abundances (Figures S3B and S3C). We also noted that multiple 
members of the miR-200 family were associated with the EMT transcription factors ZEB1 
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and ZEB2 (Figure S3D and Table S5). Of 62 miRNAs previously associated with EMT, 14 
were anticorrelated with the EMT score at a false discovery rate <0.05 (Figure S3E).
Although the EMT scores have significant positive and negative correlations with the 
percentages of sarcoma and carcinoma, respectively, no associations were observed with 
tumor purity estimates derived from ABSOLUTE (Carter et al., 2012). UCS has an EMT 
score that is intermediate between other gynecologic tumors and sarcomas (Figure 5A). 
Using a protein-derived EMT score also demonstrates that UCS is intermediate between 
other gynecologic tumors and sarcomas (Figure 5B). The expression of 131 genes identified 
as being correlated with EMT was more strongly correlated with the EMT scores in UCS 
than in other gynecologic cancers (Figure S4A). Furthermore, of 16 tumor types analyzed by 
TCGA, UCS had the most variable EMT scores (Figure S4B). There was no association 
between EMT scores and clinical outcome (data not shown). We calculated protein 
expression-based pathway scores for nine pathways, as described previously (Akbani et al., 
2014), and correlated the nine pathway scores with the mRNA-based EMT pathway score. 
The nine pathways include apoptosis, cell cycle, DNA damage response, hormone_a, 
hormone_b, PI3K/AKT, RAS/MAPK, RTK, and TSC/mTOR. Two pathways, DNA damage 
response (R = 0.382, p = 0.007) and PI3K/AKT (R = 0.389, p = 0.006), were correlated with 
EMT (Table S6). Taken together, these findings show that, despite high tumor purity, UCS 
exhibits an epithelial-mesenchymal phenotypic diversity that distinguishes it from other 
tumors, which cannot be explained by variation in stromal content.
Multi-platform integration
We used the Illumina Infinium HumanMethylation450 (HM450) BeadChips (Illumina, San 
Diego, CA, USA) to obtain DNA methylation profiles of the 57 UCS samples. An 
unsupervised cluster analysis of DNA methylation profiles grouped the tumors into three 
main clades according to their cancer-specific hypermethylation patterns (Figure S5A). 
Unsupervised consensus clustering of the 2500 most variably expressed genes from RNA 
sequencing suggested the presence of two expression subtypes (Table S7). One group of 
tumors from the DNA methylation clustering exhibited a hypermethylation pattern similar to 
that of endometrioid UCEC, whereas the others were much more similar to the serous 
subtype (Figure S5B). This finding prompted us to examine molecular characteristics 
distinguishing endometrioid versus serous histologic subtypes in UCEC across all genomic 
platforms (Figure 6). Although most UCS tumors resembled the serous/high somatic copy 
number alteration group in UCEC, a subgroup of UCS tumors appeared to have consistently 
more endometrioid features, including fewer overall somatic copy number alterations and 
greater DNA hypermethylation, as well as differential expression exemplified by lower 
S100A1 and HIF3A and higher TP73 mRNA abundance compared to the serous histologic 
subtypes (data not shown). This subset of tumors had frequent PTEN mutations, which were 
almost exclusive to the endometrioid subtype of UCEC, suggesting an independent 
molecular mechanism underlying the development of this histologic subtype. Tumors with 
PTEN mutations had frequent amplification of chromosome 8p (p = 0.001, Fisher’s exact 
test), whereas chromosome 8q was amplified in most tumors. In contrast to the serous-
endometrioid dichotomy, the UCS tumors exhibited greater expression of mesenchymal 
genes than their carcinomatous counterparts (Figure S4A), which was proportional to the 
Cherniack et al. Page 7
Cancer Cell. Author manuscript; available in PMC 2018 March 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
microscopically observed percentage of sarcomatous versus carcinomatous content of the 
tumor (Figure 4), highlighting a parallel molecular divergence between sarcoma and 
carcinoma in addition to the bifurcation to endometrioid and serous phenotypes. UCS 
tumors with heterologous differentiation had a higher EMT score than those with 
homologous differentiation, but did not show any other distinct molecular patterns (Figure 
4).
The mismatch repair gene MLH1 was epigenetically silenced in two tumors that were 
independently identified by PCR as having high microsatellite instability (Figure S5A). 
These tumors, along with one tumor with a POLE mutation and another with an APOBEC 
mutation signature, had the highest mutation densities in the cohort (Figure 1A). No BRCA1 
promoter methylation or BRCA1 somatic mutations were found in any tumors. This 
contrasts with serous ovarian tumors, in which 12% have epigenetic silencing and 3% have 
BRCA1 somatic mutations (Cancer Genome Atlas Research, 2011). We assessed microbes 
in the UCS cohort using whole exome sequencing and RNA-seq (Figure S6). None of the 
libraries were positive for infectious agents, either de novo or when we applied our viral 
integration pipeline.
Protein expression analysis
For 48 UCS samples with sufficient material available, we used reverse phase protein arrays 
(RPPA) (Hennessy et al., 2010) to generate protein expression data for 200 proteins, 
including 51 phosphoproteins and four post-translational modifications (Table S6). 
Unsupervised clustering of the RPPA data showed two clusters containing heterogeneously 
expressed proteins and lacking consistent expression patterns (Figure S7A). We therefore 
concluded that the UCS proteomics data did not reveal reliable unsupervised subtypes.
Due to the biphasic nature of UCS and relatively high EMT scores (Byers et al., 2013), we 
explored whether the proteomic profile of UCS more closely resembled gynecologic 
carcinomas (with low EMT scores) or sarcomas (with high EMT scores). For gynecologic 
carcinomas, we used TCGA protein expression data for endometrial (UCEC) and ovarian 
(OV) carcinomas and compared them against the TCGA sarcoma data (after removing 
leiomyosarcoma samples, which had very different expression profiles from the other 
sarcoma subtypes). To distinguish the gynecologic carcinomas from the sarcomas, we 
identified the top 100 out of 200 proteins that were most differentially expressed between 
them, independent of the UCS samples. Those 100 proteins were then used to cluster the two 
groups with the UCS samples included, supervised by tumor type. Pathway analysis was 
also performed, as described previously (Akbani et al., 2014), to determine which pathways 
in UCS were similar to the gynecologic carcinomas and which were similar to the sarcomas.
UCS tumors shared some protein expression patterns that were common to the gynecologic 
carcinomas and other patterns that were similar to the sarcomas without exclusively 
resembling either group (Figure 7A). For example, similar to endometrial carcinoma, but 
unlike the sarcomas, UCS tumors had elevated expression of phospho-AKT indicating high 
activity of the PI3K/AKT pathway and suggesting that UCS may be susceptible to PI3K 
inhibitor therapy. Also similar to endometrial carcinoma, UCS showed lower activity of the 
RAS/MAPK pathway compared to the sarcomas, with lower levels of MEK1, CRAF, and 
Cherniack et al. Page 8
Cancer Cell. Author manuscript; available in PMC 2018 March 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
ARAF. By contrast and similar to the sarcomas, UCS tumors had surprisingly low levels of 
the hormone receptors ERα and AR compared to the gynecologic tumors, suggesting that 
UCS is unlikely to benefit from hormone therapy. In addition, Claudin 7, E-cadherin, and β-
catenin levels were also low, indicating high EMT, as described previously. However, UCS 
showed higher activity of the cell cycle and DNA damage response pathways than either the 
gynecologic carcinomas or sarcomas, with elevated levels of Cyclin E1 and FOXM1 (cell 
cycle pathway), and phospho-CHK2, MRE11, RAD50 and RAD51 (DNA damage response 
pathway), delineating additional future targets for therapy (Figure 7B).
The UCS samples did not exhibit a dichotomy in which some samples had features of 
gynecologic carcinomas but others had features of sarcomas; rather, they demonstrated 
features of both tumor cohorts simultaneously. We performed a similar analysis of the top 
2,000 most differentially expressed genes using the mRNA data and those results also show 
that UCS shares some gene expression profiles with gynecologic carcinomas and others with 
sarcomas (Figure S7B), indicating good agreement between the observations from the 
proteomic and transcriptomic platforms. Whether these findings represent intratumoral 
heterogeneity versus heterogeneous features at the cellular level cannot be determined from 
these data.
Discussion
This integrated genomic and proteomic analysis of 57 UCSs provides insights into disease 
biology and offers therapeutic opportunities. Our analysis identified alterations in canonical 
pathways containing therapeutic targets that are currently in clinical trials. Half of the 
samples had a mutation in a PI3K pathway gene expected to result in activation of 
downstream elements. Additionally, more than three-quarters of the cases also had mutation 
in FBXW7, amplification of CCNE1 or RB1 loss, suggesting deregulated cell cycle 
function. ARID1A, which encodes a SWI/SNF epigenetic chromatin remodeler that has 
been implicated in many tumor types (Wu and Roberts, 2013; Wu et al., 2014), was also 
frequently altered. Taken together, these findings open possibilities for PI3K/AKT pathway, 
cell cycle and epigenetic therapies in stratified subpopulations of patients with UCS. A 
number of reports indicate that inactivation of chromatin remodeling genes such as ARID1A 
and CHD4 results in susceptibility to various targeted therapies including PARP and EZH2 
inhibition (Bitler et al., 2015; Pan et al., 2012; Shen et al., 2015). A current clinical trial 
(NCT02059265) is testing the multi-target tyrosine kinase inhibitor dasatinib in clear cell 
ovarian and endometrial carcinomas with ARID1A loss (Miller et al., 2016). PI3K inhibition 
has been successful in advanced endometrial cancers with responses seen in patients with 
pathway alterations despite some limitations due to tolerability (Makker et al., 2016).
Although there was no clear evidence for traditional molecular subgroups, supervised 
comparisons with other gynecologic tumors across multiple platforms demonstrated that 
most UCS tumors share common features with high-grade serous ovarian and serous 
endometrial tumors. A minority of UCS tumors has molecular features consistent with an 
endometrioid subtype, including PTEN and KRAS mutations and corresponding gene 
expression profiles. These data support the theory that some UCS tumors develop from an 
endometrioid lineage, but most tumors likely de-differentiate from a serous precursor. De-
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differentiation from an epithelial precursor manifests through a mesenchymal phenotype, 
which might account for the aggressive nature of this tumor, and is highlighted by higher 
EMT scores in tumors that have heterologous differentiation. Individually, the UCS tumors 
have both epithelial and mesenchymal features that reflect their biphasic morphology. In 
addition to loss of cell adhesion to the basement membrane and apical-basal polarity, 
increased invasiveness and resistance to apoptosis are likely due to deregulated EMT control 
(Kalluri and Weinberg, 2009; Radisky, 2005).
The presence of EMT in tumors has been a topic of intense debate (Li and Kang, 2016; 
Savagner, 2010), although carcinosarcomas are deemed by some as bona fide examples of 
EMT in vivo (Savagner, 2010). However, it has not been ruled out that transdifferentiation in 
the other direction exists; namely, it is possible that these tumors start out as sarcoma and 
then undergo epithelial differentiation (MET instead of EMT). The mutations that we 
discovered in this study were reminiscent of what was reported in the far more common 
endometrial carcinomas. In addition, molecular features including DNA methylation, copy 
number and gene expression recapitulate the endometrial versus serous dichotomy observed 
in endometrial carcinomas, which was in line with a previous report studying genetic 
mutation (McConechy et al., 2015). This paper also identified concordant mutation profiles 
in microdissected carcinoma and sarcomatous components of primary tumors as well as 
between primary and metastatic lesions. These data all suggest a carcinoma origin and 
retention of previous ancestral molecular alterations. However, our study was not designed 
to pinpoint the directionality of transition. A recent sequencing study of microdissected 
sarcoma and carcinoma components suggests that UCS begins as carcinoma followed by 
sarcomatous transformation (Zhao et al., 2016). In vivo cell lineage tracing would also help 
to establish this directionality.
In comparison to prior work where many of the mutations in chromatin-remodeling genes, 
including CHD4 and ARID1A, were found in hypermutated UCS samples or in 
carcinosarcoma tumors of ovarian origin (Jones et al., 2014), the present study identifies 
these mutations in more than one-third of non-hypermutated UCS samples. Despite initial 
treatment with surgery and/or chemotherapy, many UCS tumors recur, with limited salvage 
treatment options. The array of targets identified in this study provides compelling 
opportunities to develop molecularly driven clinical trials to individualize and improve 
cancer care for primary or recurrent UCSs. Combined with its rarity, the diverse molecular 
landscape of UCS tumors supports clinical trials in cooperative groups to develop 
independent treatment paradigms. These approaches have an opportunity to improve the 
outcome of women with this unique solid tumor.
Experimental procedures
Detailed description of each analysis presented in this study can be found within the 
Supplemental Experimental Procedures.
Biospecimen collection and clinical data
Biospecimens were collected at diagnosis after obtaining informed consent from patients 
with uterine carcinosarcoma. Local Institutional Review Board approval was obtained from 
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Cedars-Sinai Medical Center, Duke University, ILSbio, LLC., Mayo Clinic, MD Anderson, 
Memorial Sloan Kettering Cancer Center, Roswell Park Cancer Institute, University of 
North Carolina, University of Oklahoma Health Sciences Center, University of Pittsburgh, 
and Washington University. Patients were selected only if their treatment plan required 
surgical resection and had received no prior treatment for their disease, including 
chemotherapy or radiotherapy. Each frozen primary tumor specimen had a companion 
normal tissue specimen.
Copy number analysis
DNA from each tumor or germline sample was hybridized to Affymetrix SNP 6.0 arrays. 
For each tumor, genome-wide copy number estimates were refined using tangent 
normalization, in which tumor signal intensities are divided by signal intensities from the 
linear combination of all normal samples that are most similar to the tumor. Significant focal 
copy number alterations were identified from segmented data using GISTIC 2.0. Allelic 
copy number, regions of homozygous deletions, whole genome doubling and purity and 
ploidy estimates were calculated using the ABSOLUTE algorithm.
Mutational Analysis
From each sample, 0.5–3 micrograms of DNA were used to prepare the sequencing library 
through shearing of the DNA followed by ligation of sequencing adaptors. Whole exome 
capture was performed using Agilent SureSelect Human All Exon protocol according to the 
manufacturers’ instructions. Basic alignment and sequence QC was done on the “Picard” 
and “Firehose” pipelines at the Broad Institute. Mutations from each calling center were 
combined into a single Mutation Annotation Format list (https://wiki.nci.nih.gov/display/
TCGA/Mutation+Annotation+Format+%28MAF%29+Specification) and labeled according 
to the centers that detected each mutation with additional fields counting reference and 
alternate supporting allele counts from each center.
Each candidate mutation site was assessed in the matched RNA-seq tumor data to identify 
candidate mutations with independent confirmation from RNA. 35.6% of the candidate 
mutations occurred at expressed sites in the RNA-seq with sufficient coverage for >90% 
power to detect the mutation observed in the tumor DNA. The final list candidate mutations 
required that two or more centers made the call or that the mutation was supported by RNA-
seq. Genes with a significant excess of the number of non-synonymous mutations relative to 
the estimated density of background mutations were identified using the MutSig algorithm 
(Lawrence et al., 2014; Lawrence et al., 2013).
Array-based DNA methylation assay
We used the Illumina Infinium HumanMethylation450 (HM450) BeadChips (Illumina, San 
Diego, CA) to obtain DNA methylation profiles of 57 uterine carcinosarcoma (UCS) 
samples. We performed bisulfite conversion on 1 μg of genomic DNA from each sample 
using the EZ-96 DNA Methylation Kit (Zymo Research, Irvine, CA) according to the 
manufacturer’s instructions. Bisulfite-converted DNA was whole genome amplified (WGA) 
and enzymatically fragmented prior to hybridization to the arrays.
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RNA sequencing
One μg of total RNA was converted to mRNA libraries using the lllumina mRNA TruSeq kit 
(RS-122-2001 or RS-122-2002) following the manufacturer’s directions. Libraries were 
sequenced 48×7×48bp on the Illumina HiSeq 2000. FASTQ files were generated by 
CASAVA. RNA reads were aligned to the hg19 genome assembly. Gene expression 
measurements were obtained by replacing all RSEM values identically equal to zero with 
the smallest non-zero RSEM value, applying a log2 transformation, and median centering by 
gene. Using the median absolute deviation, the 2500 most variably expressed genes were 
identified. Consensus clustering was then performed.
miRNA Sequencing
We generated microRNA sequence (miRNA-seq) data for 57 tumor samples using 1 μg of 
total RNA (at 250 ng/μL) as input. We aligned reads to the GRCh37/hg19 reference human 
genome, and annotated miRNA read count abundance with miRBase v16. We used miRBase 
v20 to assign 5p and 3p mature strand (miR) names to MIMAT accession IDs. We identified 
groups of samples that had similar abundance profiles using unsupervised non-negative 
matrix factorization (NMF) consensus clustering.
Reverse-Phase protein array
Protein was extracted using RPPA lysis buffer from human tumors and RPPA was 
performed. Tumor lysates were manually serial diluted in two-fold of 5 dilutions with lysis 
buffer. Slides were probed with 200 validated primary antibodies followed by corresponding 
secondary antibodies. We performed median centering across all the antibodies for each 
sample to correct for sample loading differences.
Data Access
Data used to generate the analyses and all of the primary sequence files are deposited in the 
NCI’s Genomic Data Commons (https://gdc.cancer.gov/). The data can be explored via the 
cBio Cancer Genomics Portal (http://cbioportal.org).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Significance
UCSs are fascinating tumors that contain morphologic components of both epithelial and 
mesenchymal cell types. They are thought to arise from a metaplastic conversion due to a 
strong EMT. Here we report an integrated genomic, epigenomic, transcriptomic and 
proteomic analysis of UCSs. We identify multiple somatic mutations and copy number 
alterations that offer expanded therapeutic options including potential use of PARP, 
EZH2, cell cycle and PI3K pathway inhibitors. We also dissect the interaction between 
the genomic and epigenomic regulation of EMT in UCSs highlighting the epigenetic 
alterations at microRNA promoters. The EMT features recognized in UCSs provide a 
mechanistic basis for the conversion of serous-like endometrial carcinoma precursors in a 
majority of cases.
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Highlights
• Uterine carcinosarcomas (UCS) have frequent TP53 mutations
• UCS demonstrate a strong and varied degree of epithelial-mesenchymal 
transition
• MicroRNA expression in UCS is under epigenetic control
• Multiple alterations are present in UCS in genes that are therapeutic targets
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Figure 1. Landscape of somatic alterations in 57 uterine carcinosarcomas
(A) Synonymous (syn.) and non-synonymous (non syn.) mutation density (mutations/Mb) 
across the cohort. (B) Gene-sample matrix of mutations in MutSig 2CV significant genes 
(Benjamini-Hochberg false-discovery rate q value < 0.1, left). Samples with kinase-domain 
fusions are shown below the mutations. Samples are ordered by number of mutations in 
significant genes. (C) Tumor stage, histologic subtype, carcinoma and sarcoma percentages, 
mutation signature type, purity and ploidy across the cohort. (D) Mutational signatures 
discovered in UCS cohort. A variant of non-negative matrix factorization (Bayesian NMF) 
to the mutation count matrix across samples (101 by 57). The vertical scale represents 
counts of mutations in each context bin labeled on the horizontal axis. Indel counts and bins 
are shown on the right. MSI, Micro-satellite instability. IND=1–4 refer to one, two, three, or 
four or more base indels. (E) Heatmap of focal somatic copy number (SCN) alterations (top) 
in genes with the highest GISTIC2 significance (right) for deletions (top 4), amplifications 
(lower 4), as well as for TP53 and PTEN, which were not significantly altered. The SCN 
ratio scale is corrected by purity and ploidy for each sample. Also shown is the arm-level 
SCN chromosome-sample heatmap across the cohort (bottom). See also Figures S1 and S2 
and Tables S1 – S4.
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Figure 2. Clinically relevant alterations in uterine carcinosarcoma
(A) Landscape of potentially clinically relevant mutations, copy number alterations and 
fusions in 56 UCS tumors, as identified by the PHIAL algorithm. Rows represent alterations 
in genes that lead to a given clinical rationale. Somatic mutations are shown in gray, 
homozygous deletions in blue, high-level amplifications in red (focal and more than two 
copies gained) and gene fusions in green. One POLE hypermutator case is excluded. (B) 
Mutation positions in amino acid coordinates for 4 of 14 significantly mutated genes. Each 
mutation is annotated by protein change (Gencode v18 transcripts). Also marked in red lines 
are sites of mutations from COSMIC v67 for which more than 5 experiments or samples had 
a mutation at the site.
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Figure 3. Clonality of UCS tumors compared with other TCGA tumor types
(A) Sorted mutation counts for each tumor separated by tumor type. All mutations are 
plotted in blue, clonal mutations in red, mutations in Significantly Mutated Genes (SMG) 
are light blue and clonal SMG mutations in magenta. All data was uniformly processed 
through the ABSOLUTE pipeline that includes adjustment for cellularity. SMGs for other 
tumor types were based on www.tumorportal.org (Lawrence et al., 2014). Labels across the 
top of the plot indicate the count of tumors included for each tumor type. (B) Boxplots 
showing the clonal proportion of mutations. Boxplot center lines (red) represent tumor 
medians, box limits (blue) are the inter-quartile range from 25% and 75%, whiskers (black) 
represent the extent of tumors out to 1.5 times the inter-quartile range, and red crosses are 
outliers beyond 1.5 times the inter-quartile range. (C) Boxplots showing the clonal 
proportion of SMGs. Components of the figure are as defined in panel (B). BLCA, bladder 
urothelial carcinoma; BRCA, breast invasive carcinoma; GBM, glioblastoma; KICH, kidney 
chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell 
carcinoma; LGG, low grade glioma; LUAD, lung adenocarcinoma; LUSC, lung squamous 
cell carcinoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; THCA 
thyroid carcinoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine 
carcinosarcoma.
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Figure 4. Evidence of EMT in uterine carcinosarcoma
The heatmap shows methylation levels for miR-200 family members, expression of miR-200 
family members, expression of select genes associated with EMT and protein expression of 
genes associated with EMT. Methylation and expression levels are median-centered by row 
and scaled by platform for visualization purposes. One DNA methylation probe from 
multiple highly correlated probes that map to the promoter of each miRNA cluster is shown 
(miR-200a/200b/429 = cg15822328, miR-141/200c = cg24702147). Samples (n = 57) 
appear in columns and are ordered according to EMT score, as shown by the histogram at 
the top. Annotation tracks at the bottom show mutation status for significantly mutated 
genes, as well as values of clinical variables of interest. Missing values (NA) for protein 
expression (n = 9) and tumor purity (n = 2) are indicated. Wilcoxon rank sum tests were 
used to assess the significance of associations between EMT scores and either gene 
mutations or histological type; Spearman correlation tests were used to assess the 
significance of associations between EMT scores and tumor purity, carcinoma percentage, 
and sarcoma percentage. Asterisks indicate statistically significant p values: *p < 0.05; **p 
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< 0.01; ***p < 0.001. E, epithelial; M, mesenchymal; EMT, epithelial-to-mesenchymal 
transition. See also Figure S3 and Table S5.
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Figure 5. Expression and quantification of EMT across tumor types
(A) The boxplot display shows differences of EMT scores within five groups of tumors: 
UCS, endometrioid UCEC, serous UCEC, OV, SARC (ANOVA p value < 0.001). Boxplot 
center lines represent tumor medians, box limits are the inter-quartile range from 25% and 
75%, whiskers represent the extent of tumors out to 1.5 times the inter-quartile range. The 
dashed horizontal line corresponds to an EMT score of 0. (B) Boxplot display shows 
differences in protein-based EMT scores within five groups of tumors: UCS, endometrioid 
UCEC, serous UCEC, OV, SARC (ANOVA p value < 0.001). Components of the figure are 
as defined in panel (A). E, epithelial; M, mesenchymal; EMT, epithelial-to-mesenchymal 
transition, UCS, uterine carcinosarcoma; UCEC, uterine corpus endometrial carcinoma; OV, 
ovarian serous carcinoma; SARC, sarcoma. See also Figure S4.
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Figure 6. Comparison of TCGA gynecological cancers
Molecular features distinguishing serous versus endometrioid uterine carcinomas (UCEC) 
for DNA methylation and mRNA expression are shown for UCEC, OV and UCS samples 
(columns). In addition, all segments for DNA copy number are displayed, with blue and red 
indicating deletion and amplification respectively. Within each tumor group, the samples are 
ranked by increasing similarity to serous UCEC and decreasing similarity to endometrioid 
UCEC (as measured by a combined rank of difference in each tumor’s distance to the 
endometrioid UCEC centroid and serous UCEC centroid from four different platforms; see 
Supplemental Experimental Procedures). Top color bars denote molecular subtype (if 
UCEC: blue – POLE; green – MSI; orange – copy number low; red – copy number high), 
PTEN mutation, TP53 mutation (black – mutant; gray – wild-type; white - missing), and 
percent endometrioid content as estimated from slide review (for UCS: blue to red for 0% to 
100%). One UCS sample failed DNA copy number analyses resulting in a total of 56 UCS 
samples for integrated analyses. See also Figures S5 and S6 and Table S7.
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Figure 7. RPPA analysis demonstrating shared epithelial and mesenchymal features of UCS 
tumors
(A) Supervised clustering heatmap showing the top 100 differentially expressed proteins 
between the gynecologic cancers (endometrial [UCEC] and ovarian [OV]) versus sarcomas 
[SARC] (without the leiomyosarcoma subtype). UCS was then added and the samples were 
clustered within each tumor type, but not across tumor types. The top half shows proteins 
that are not highly expressed in sarcomas, whereas the bottom half shows proteins that are 
highly expressed in sarcomas. The arrows point to proteins of interest color-coded to reflect 
pathway membership. UCS proteins outlined in purple have similar profiles to the 
gynecologic cancers and proteins outlined in green have profiles similar to sarcoma. (B) Box 
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plots of pathway activities showing how UCS compares with UCEC, OV and SARC. 
Sample size of each tumor type is the same as panel (A). Boxplot center lines represent 
tumor medians, box limits are the inter-quartile range from 25% and 75%, whiskers 
represent the extent of tumors out to 1.5 times the inter-quartile range, and circles are 
outliers beyond 1.5 times the inter-quartile range. ANOVA-based p values are shown for 
each plot, indicating the statistical significance of the differences between the boxes. See 
also Figure S7 and Table S6.
Cherniack et al. Page 26
Cancer Cell. Author manuscript; available in PMC 2018 March 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
